<DOC>
	<DOCNO>NCT00454532</DOCNO>
	<brief_summary>BZL 101 aqueous extract herba Scutellaria Barbata D. Don Lamiaceae family . Preclinical study suggest herb antitumor activity breast cancer preliminary clinical data suggest tolerable patient metastatic breast cancer . The overall goal Phase I/II trial ass toxicity , maximum tolerate dose , safety preliminary efficacy BZL101 treatment advance metastatic breast cancer .</brief_summary>
	<brief_title>A Phase I/II Clinical Trial Assessing Safety Efficacy BZL101 Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Key Women 18 year old Histologically confirm breast cancer Clinical evidence metastatic ( stage IV ) metastasis ( bone metastasis ) Availability estrogen progesterone receptor status At least one measurable disease site define RECIST criterion , 30 day prior study therapy For phase 1 , 3 prior cytotoxic regimen metastatic breast cancer . For phase 2 , 2 prior cytotoxic regimen metastatic breast cancer Life expectancy ≥ 12 week Eastern Cooperative Oncology Group performance status ≤2 Women child bear potential must agree 2 form contraception course trial . Key Inability understand/unwillingness sign write informed consent Any significant side effect relate prior chemo , radiation , biology hormonal therapy resolve judgment investigator Currently use investigational agent Clinically significant gastrointestinal abnormality Currently use coumadin therapeutic dos within 2 week take study medication Concurrent palliative radiation anticancer treatment Women report pregnancy , breastfeed positive pregnancy test</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Bionovo</keyword>
	<keyword>BZL101</keyword>
	<keyword>Chinese Herbs</keyword>
</DOC>